ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home TMB

Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin Filipits

on: April 15, 2020In: Evolving Standards of Care
Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin Filipits

Posted: April 16, 2020 As we know, molecular marker identification allows for more rational use of existing therapies. When markers can be identified more effectively and quickly, patient care advances. […] Read more


Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

on: February 12, 2020In: Diagnostic Oncology
Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients […] Read more

CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC

on: February 11, 2020In: Evolving Standards of Care
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC

By Neal Ready, MD, PhD Posted: February 12, 2020 Dr. Neal Ready Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of advanced […] Read more

2019 IASLC World Conference on Lung Cancer Updates

on: November 11, 2019In: Meeting News
2019 IASLC World Conference on Lung Cancer Updates

Posted: November 12, 2019 More than 7,700 delegates from around the world attended the IASLC 2019 World Conference on Lung Cancer (WCLC). With sessions and workshops on every aspect of […] Read more

SEARCH ILCN

Archives

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy